

**MAIL STOP PCT**  
Attorney Docket No. 27550U  
Preliminary Amendment

**REMARKS**

The above amendments have been made to remove multiple dependencies to the claims and conform them to U.S. practice.

No new matter has been added.

Respectfully submitted,

**NATH & ASSOCIATES PLLC**

By: 

Gary M. Nath  
Registration No. 26,965  
Susanne M. Hopkins  
Registration No. 33,247  
**Customer no. 20529**

Date: July 28, 2006  
NATH & ASSOCIATES  
112 South West Street  
Alexandria, VA 22314  
GMN/SMH/dd:AMENDpreml

## **ATTACHMENT A**

### **CLAIMS:**

#### **1-39 (canceled)**

**40. (new)** A method for diagnosing breast cancer in a subject comprising determining levels of expression of p14 peptide in one or more samples from said subject, a high level of expression signifying a high probability for breast cancer in said subject.

**41. (new)** The method of Claim 40, comprising assaying for the level of p14 peptide in a sample obtained from the subject, said method comprises:

- (a) contacting said sample with anti-p14 antibodies;
- (b) determining binding of anti-p14 antibodies to p14 peptide.

**42. (new)** The method of Claim 41, wherein said sample is a tissue or body fluid sample excised or withdrawn from a suspicious area in the breast of the subject.

**43. (new)** The method of Claim 42, wherein said sample is selected from fresh biopsy section, cryo-section or paraffin embedded section.

**44. (new)** The method of Claim 40, wherein said sample is a blood sample.

**45. (new)** The method of Claim 40, comprising assaying for the level of anti-p14 antibodies in a sample obtained from the subject, said method comprises:

- (a) contacting said sample with p14 peptide;
- (b) determining binding of p14 peptide to anti-p14 antibodies.

**46. (new)** The method of Claim 45, wherein said p14 peptide is His-tag p14 peptide comprising the sequence depicted in SEQ ID NO:2.

**47. (new)** A method for screening samples into such which signify that subjects from which they were obtained have a relatively high possibility of having or being susceptible of developing breast cancer and such which signify that subjects from which they were obtained have a relatively lower probability of having or

being susceptible of developing breast cancer, the method comprising contacting the samples with anti-p14 antibodies and determining binding of anti-p14 antibodies and p14 peptide in said sample, a high degree of binding signifying a corresponding higher probability of having or being susceptible of developing breast cancer.

**48.** (new) The method of Claim 47, wherein said sample is a tissue or fluid sample excised or withdrawn from a suspicious area in the breast of the subject.

**49.** (new) The method of Claim 48, wherein said sample is selected from fresh biopsy section, cryo-section or paraffin embedded section.

**50.** (new) The method of Claim 49, wherein said sample is a blood sample.

**51.** (new) A method for screening samples into such which signify that subjects from which they were obtained have a relatively high possibility of having or being susceptible of developing breast cancer and such which signify that subjects from which they were obtained have a relatively lower probability of having or being susceptible of developing breast cancer, the method comprising contacting the samples with p14 peptide and determining binding of p14 peptide with anti-p14 antibodies, a high degree of binding signifying a corresponding higher probability of having or being susceptible of developing breast cancer.

**52.** (new) The method of Claim 51, wherein said sample is a blood sample.

**53.** (new) The method of Claim 52, wherein said p14 peptide is His-tag p14 peptide comprising the sequence depicted in SEQ ID NO:2.

**54.** (new) A method for the treatment of breast cancer comprising administering to a subject in need of anti-breast cancer treatment an amount of anti-p14 antibodies, the amount being sufficient to achieve an anti cancer effect in said subject.

**55.** (new) The method of Claim 54, wherein said anti-p14 antibodies are humanized antibodies.

**56.** (new) The method of Claim 54, wherein said anti-p14 antibodies are bound to a protein transducing element.

**57.** (new) The method of Claim 56, wherein said protein transducing element is the (37-72) Tat fragment of HIV-HV1B1 Tat.

58. (new) The method of Claim 54, wherein said anti-p14 antibodies are bound to a cytotoxic agent.
59. (new) A method for the treatment of breast cancer comprising administering to a subject in need an amount of p14 peptide, the amount being effective to elicit production of anti-p14 antibodies in said subject.
60. (new) A pharmaceutical composition for the treatment of breast cancer comprising as active ingredient an amount of anti-p14 antibodies, the amount being sufficient to achieve a therapeutic effect in said subject.
61. (new) The pharmaceutical composition of Claim 60, wherein said anti-p14 antibodies are humanized antibodies.
62. (new) The pharmaceutical composition of Claim 61, wherein said anti-p14 antibodies are bound to a protein transducing element.
63. (new) The pharmaceutical composition of Claim 62, wherein said protein transducing element is the (37-72) Tat fragment of HIV-HV1B1 Tat.
64. (new) The pharmaceutical composition of Claim 60, wherein said anti-p14 antibodies are bound to a cytotoxic agent.
65. (new) A vaccine comprising as active ingredient an amount of p14 peptide or an immunogenic fragment thereof, the amount being sufficient to elicit in a subject production of anti-p14 antibodies.